Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 210,000 Shares of Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Jason Daly sold 210,000 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the transaction, the executive vice president owned 35,171 shares of the company’s stock, valued at approximately $611,975.40. This represents a 85.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Amneal Pharmaceuticals Price Performance

Shares of Amneal Pharmaceuticals stock traded down $0.39 during trading on Thursday, hitting $17.27. 2,244,046 shares of the company’s stock traded hands, compared to its average volume of 2,168,140. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.44. The firm’s fifty day moving average price is $17.08 and its 200 day moving average price is $14.54. Amneal Pharmaceuticals, Inc. has a twelve month low of $9.15 and a twelve month high of $19.26. The company has a market cap of $5.51 billion, a PE ratio of 35.24 and a beta of 1.27.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AMRX. The Goldman Sachs Group reiterated a “buy” rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Zacks Research upgraded Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. Barclays increased their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Finally, UBS Group lifted their price objective on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $17.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Globeflex Capital L P bought a new stake in Amneal Pharmaceuticals during the 2nd quarter worth approximately $2,536,000. Bank of New York Mellon Corp bought a new position in Amneal Pharmaceuticals in the 2nd quarter valued at $17,573,000. Handelsbanken Fonder AB raised its position in Amneal Pharmaceuticals by 3.0% in the 2nd quarter. Handelsbanken Fonder AB now owns 76,400 shares of the company’s stock valued at $1,322,000 after purchasing an additional 2,200 shares during the last quarter. Bank of America Corp DE boosted its stake in Amneal Pharmaceuticals by 50.0% in the first quarter. Bank of America Corp DE now owns 676,795 shares of the company’s stock worth $8,413,000 after purchasing an additional 225,637 shares in the last quarter. Finally, Arkadios Wealth Advisors bought a new stake in shares of Amneal Pharmaceuticals during the first quarter worth $4,165,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.